Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237572 · ClinicalTrials.gov registry record · Phase 1
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
A Phase 1 study, sponsored by Patrick Dillon, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03237572: Clinical Trial Phase 1 study, sponsored by Patrick Dillon, MD.
NCT03237572 is a Phase 1 study that was terminated before completion, run by Patrick Dillon, MD. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03237572, a Phase 1 study, was terminated before completion, sponsored by Patrick Dillon, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.
Primary Outcome
How many of the immune cells inside a tumor are a specific type of "killer" T cell
Interventions
- DRUG Pembrolizumab
- DEVICE High-intensity focused ultrasound (HIFU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2022-06-17 |
| Phase | Phase 1 |
Why NCT03237572 stopped before completion
NCT03237572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03237572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03237572 about?
NCT03237572 is a clinical study titled "Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer". This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to r...
What is the current status of trial NCT03237572?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-09-25. Estimated completion is 2022-06-17.
What interventions are being tested in trial NCT03237572?
The interventions under investigation include: Pembrolizumab (DRUG), High-intensity focused ultrasound (HIFU) (DEVICE).
Who is sponsoring clinical trial NCT03237572?
This trial is sponsored by Patrick Dillon, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03237572's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI